Molecular profiling for treating pediatric and young adult cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

MAPPYACTS 2 is an international multicentric clinical initiative aimed at providing tailored therapeutic recommendations based on the molecular characteristics of tumors in pediatric and young adult patients with relapsed or refractory malignancies. The study utilizes advanced genomic techniques, including Whole Exome Sequencing and RNA Sequencing, to identify genomic alterations that may inform targeted treatment options. It also aims to create a comprehensive clinical database to track treatment outcomes and enhance patient care through collaboration among biologists, scientists, and physicians. The program will link to interventional studies and ancillary research to foster the development of new treatment strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient referred for sequencing of the tumor within the FMG2025 or equivalent program and written consent for FMG2025 - Cancers et leucémies pédiatriques en échec de traitement or equivalent signed
* Written informed consent for MAPPYACTS 2 (or non-opposition for retrospective clinical data collection) according to local or national regulations
* Patient with confirmed solid tumor or leukemia which is relapsed or refractory to standard treatment and who is potentially eligible for an experimental treatment or an early phase clinical trial at the time of tumor sequencing
* Planned tumor biopsy, surgical resection, bone marrow or blood sample or recently (possibly within the last 3 months) archived frozen tumor material available of the current recurrent or refractory disease
* Patients aged ≤ 25 years at the time of initial diagnosis
* Performance status and life expectancy \> 3 months at the time of tumor sequencing that allows enrolment into an experimental trial
* Patients affiliated with a Social Security Regimen or beneficiary of the same as per local regulatory requirements

Exclusion Criteria:

* Any concurrent illness or laboratory abnormality that, in the opinion of the investigator, is likely to interfere with the interpretation of study results
* Pregnant women

Where it's running

• CHU Amiens-Picardie
  Amiens, France, France Recruiting
• Hopital Armand Trousseau
  Paris, France, France Recruiting
• CHU Saint Etienne
  Saint-Etienne, France, France Recruiting
• Gustave Roussy
  Paris, Villejuif, France Recruiting
• CHU Angers
  Angers, France Recruiting
• CHU Besançon
  Besançon, France Recruiting

Study contacts

• Principal investigator: Birgit GEOERGER, MD — Gustave Roussy, Cancer Campus, Grand Paris
• Study coordinator: Birgit GEOERGER, MD
• Email: Birgit.GEOERGER@gustaveroussy.fr
• Phone: +33 (0)1 42 11 46 61

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• A network for collaborative cancer research in Ontario

  This study is testing a new way to improve cancer treatment by using genetics and technology to help personalize care for people with different types of cancer.

  Recruiting at 2 sites University Health Network, Toronto · Kingston, Ontario and 2 other locations · NCT05403177

• Long-term follow-up for childhood cancer survivors

  This study is trying to keep in touch with childhood cancer survivors to see how they are doing over time and understand the long-term effects of their treatments.

  Recruiting at 139 sites Children's Oncology Group · Birmingham, Alabama and 163 other locations · NCT00736749

• SumMET: Targeted radioligand therapy for c-MET–positive solid tumors

  This first‑in‑human study tests the safety and potential effectiveness of a radioligand therapy called [225Ac]Ac-FL-261 in adults with advanced or metastatic solid tumors that overexpress c-MET.

  Recruiting at 2 sites Phase 1/2 Full-Life Technologies UK Limited · Minneapolis, Minnesota and 1 other locations · NCT07873450

• SHR-4595 Injection in Advanced Solid Tumors: Safety, Tolerability, and Dosing in Phase 1

  This early-phase trial tests SHR-4595 injections to see if they are safe and tolerable for adults with advanced solid tumors who have exhausted standard treatments.

  Recruiting at 2 sites Phase 1 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Shenyang, Liaoning and 1 other locations · NCT07830199

• FAPI PET imaging with FAPI-RuiJ and FAPI-04 in solid tumors

  This study tests two FAP-targeted PET tracers (FAPI-RuiJ and FAPI-04) to see which better detects, stages, and monitors solid tumors.

  Recruiting Ruijin Hospital · Shanghai · NCT07776899

• Trop-2 Targeted PET/CT for Recurrent and Metastatic Thyroid Cancer

  This study tests whether a Trop-2 targeted PET/CT scan can better detect recurrent or metastatic thyroid cancer in adults than another PET/CT scan (FAPI).

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07753499

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.